Here is the design of a clinical trial:

Official Title: Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Included conditions:
- Endometrial Cancer

Study Armgroups:
- {'label': 'Enhanced usual care', 'type': 'NO_INTERVENTION', 'description': 'Written materials in an appealing package.'}
- {'label': 'Facilitated group support', 'type': 'ACTIVE_COMPARATOR', 'description': 'Weekly group gatherings.', 'interventionNames': ['Behavioral: Facilitated group support']}
- {'label': '1:1 Peer Support', 'type': 'ACTIVE_COMPARATOR', 'description': 'Individual peer support calls.', 'interventionNames': ['Behavioral: 1:1 Peer Support']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Facilitated group support', 'description': 'Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.', 'armGroupLabels': ['Facilitated group support']}
- {'type': 'BEHAVIORAL', 'name': '1:1 Peer Support', 'description': '1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.', 'armGroupLabels': ['1:1 Peer Support']}

Primary Outcomes:
- {'measure': 'Treatment completion (relative dose)', 'description': 'Relative dose is the ratio of actual-to-expected total dose of treatment received. The calculation of expected total dose will be made from the baseline treatment recommendation data collected at enrollment.', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
The study assumes a type 1 error rate of 0.025 with a conservative Bonferroni correction for two statistical tests. Covariate adjustment for SPS-24 measured at baseline is planned, assuming a correlation of 0.3 between baseline and 6-month SPS-24. The sample size for the Facilitated Support Group is increased by 30% due to potential correlation among participants, assuming an intraclass correlation coefficient of 0.12 and an average group size of 4. The study also accounts for a 7-8% loss to follow-up and missing data.
Sample size
        A study sample size of nÂ =Â 252 was established to provide a minimum of 80% statistical power for the secondary outcome of SPS-24 social isolation, and >80% power for the primary outcome of treatment completion. Sample size estimation accounted for a type 1 error rate of 0.025 to accommodate a conservative Bonferroni correction for two statistical tests of the primary end point (enhanced usual care vs 1:1 peer support, enhanced usual care vs facilitated support group). We plan to use covariate adjustment for SPS-24 measured at baseline as one would do in a traditional analysis of covariance (ANCOVA) model and conservatively assumed a correlation between baseline and 6-month SPS-24 of 0.3. A minimum of nÂ =Â 70 participants are required in each intervention arm to detect an effect size 4.0 points (standard deviation of 8.0) with 80% power, a change that represents the total absence or presence of one aspect of each of the subscales. Due to the group nature of the Facilitated Support Group intervention, outcomes among participants randomized to this intervention may be correlated with one another. We therefore increased the sample size for the Facilitated Support Group by 30% (variance inflation factorÂ =Â 1.30), assuming an intraclass correlation coefficient of 0.12 and average anticipated group size of 4. Finally, we accounted for possible loss to follow-up and missing data of 7â8% [41]. These calculations resulted in a total sample size of 252 participants (76 enhanced usual care, 100 facilitated support group, and 76 1:1 peer support). With this sample size, the study has 84% power to detect an absolute improvement in relative dose of 6.5% or larger, which represents a small but meaningful improvement in treatment completion relative to improvements observed in other studies (8â16%) [30].